Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus

被引:80
|
作者
Nomura, S
Shouzu, A
Omoto, S
Nishikawa, M
Iwasaka, T
机构
[1] Kansai Med Univ, Dept Internal Med 1, Moriguchi, Osaka 5708507, Japan
[2] Kansai Med Univ, Dept Internal Med 2, Moriguchi, Osaka 5708507, Japan
关键词
monocyte; derived microparticle; type 2 diabetes mellitus; hypertension; angiotensin II receptor blocker; statin;
D O I
10.1177/107602960401000203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monocyte-derived microparticles play an important role in the pathogenesis of diabetic vasculopathy, and angiotensin II receptor blocker and statin have been shown to have a beneficial effect on the angiopathies of hypertension and hyperglycemia in patients with type 2 diabetes mellitus. However, the interaction between angiotensin II receptor blocker and statin, and monocyte-derived microparticles in atherosclerosis is poorly understood. The effects of losartan and simvastatin on circulating concentrations of monocyte-derived microparticles, chemokines, and soluble adhesion markers were studied in hypertensive patients with or without type 2 diabetes mellitus. Monocyte-derived microparticles were measured by flow cytometry, and levels of serum chemokines (MCP-1 and RANTES) and soluble adhesion markers (sP-selectin and sVCAM-1) were measured by enzyme-linked immunosorbent assay. Losartan decreased both the systolic and diastolic blood pressure in hypertensive patients with and without type 2 diabetes mellitus. The concentrations of monocyte-derived microparticles, chemokines, and soluble adhesion molecules were higher in hypertensive patients who also had type 2 diabetes mellitus vs. those who did not. The administration of angiotensin II receptor blocker decreased the circulating concentration of all these markers. In addition, all markers were decreased by combination therapy, and monocyte-derived microparticles were decreased more with combination therapy with losartan and simvastatin than monotherapy with losartan. The administration of angiotensin II receptor blocker inhibited monocyte-derived microparticle generation and suggests that angiotensin II is intimately related to vascular changes that occur in type 2 diabetes mellitus. Combination therapy with a statin and angictensin II receptor blocker might be valuable as anti-atherosclerotic therapy in patients with type 2 diabetes mellitus and nephropathy.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 50 条
  • [21] The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients
    Han, Seung Hwan
    Koh, Kwang Kon
    Quon, Michael J.
    Lee, Yonghee
    Shin, Eak Kyun
    ATHEROSCLEROSIS, 2007, 190 (01) : 205 - 211
  • [22] Dermatoglyphics and Cheiloscopy patterns in hypertensive and type 2 Diabetes mellitus patients: An observational study
    Mouneshkumar, C. D.
    Anand, Santosh
    Shilpa, R. H.
    Haidry, Nazia
    Kulkanil, Pranay
    Aastha
    Gupta, Aaysha
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (03) : 1177 - 1182
  • [23] C-peptide as a new hypertensive factor in patients with type 2 diabetes mellitus
    Fernandez, E
    Bernal, E
    Sanchez, O
    Sanchez-Largo, E
    Coca-Robinot, D
    Fabregate, R
    Marquez, J
    Monge, B
    Saban-Ruiz, J
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 179A - 179A
  • [24] High prevalence of masked hypertension in treated hypertensive patients with type 2 diabetes mellitus
    Alsuwaida, K
    Parkes, R
    So, J
    Feig, D
    Logan, A
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 35A - 35A
  • [25] Reproducibility of ambulatory blood pressure monitoring in hypertensive patients with type 2 diabetes mellitus
    Felicio, Joao Soares
    Pacheco, Juliana Torres
    Ferreira, Sandra Roberta
    Plavnik, Frida
    Kohlmann, Oswaldo
    Ribeiro, Artur Beltrame
    Zanella, Maria Tereza
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2007, 88 (02) : 207 - 211
  • [26] Renalase gene polymorphisms in patients with type 2 diabetes mellitus with and without hypertension
    Wael Refaie
    Ahmad Elewa
    The Egyptian Journal of Internal Medicine, 2013, 25 (3) : 149 - 153
  • [27] BIOMARKERS OF MYOCARDIAL FIBROSIS AND RENAL DYSFUNCTION IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Bilovol, Oleksandr M.
    Kniazkova, Iryna I.
    Kirienko, Oleksandr M.
    Bogun, Maryna, V
    Kirienko, Denis M.
    Abramova, Lilya P.
    Berezin, Alexander E.
    PHARMACOPHORE, 2020, 11 (06): : 132 - 140
  • [28] Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study)
    Buscemi, Silvio
    Buscemi, Carola
    Borzi, Antonio Maria
    Cosentino, Loretta
    Rosafio, Giuseppe
    Randazzo, Cristiana
    Colomba, Daniela
    Di Raimondo, Domenico
    Pluchinotta, Francesca Romana
    Parrinello, Gaspare
    METABOLIC SYNDROME AND RELATED DISORDERS, 2020, 18 (02) : 110 - 118
  • [29] Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria
    Osvaldo Kohlmann
    Alejandro Roca-Cusachs
    Stéphane Laurent
    Roland E. Schmieder
    René R. Wenzel
    Roberto Fogari
    Advances in Therapy, 2009, 26
  • [30] Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria
    Kohlmann, Osvaldo, Jr.
    Roca-Cusachs, Alejandro
    Laurent, Stephane
    Schmieder, Roland E.
    Wenzel, Rene R.
    Fogari, Roberto
    ADVANCES IN THERAPY, 2009, 26 (03) : 313 - 324